Sign in
Taking people in United StatesPhase 3

A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control

Key facts

Who runs it
Jaeb Center for Health Research
Where
Birmingham, Boston, Chicago, Columbus, Durham, Fullerton, Grand Rapids, Houston, Lancaster, Nashville, Norfolk, Palo Alto, Philadelphia, Portland, Salt Lake City, and Tucson, United StatesSee the 18 sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
348 people, planned
Started
1 Jul 2026
Expected to end
1 Jan 2030
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Atropine
  • Spectacles with HAL
  • Placebo Eyedrops
Record updated
2 November 2026

Who can take part

Age
5 years to 11 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Age 5 years to <12 years at time of enrollment. Children within 4 weeks of their 12th birthday are not eligible
  • Refractive error meeting the following by cycloplegic autorefraction:; Myopia of 0.75D to 6.00D SER and at least 0.75D in both principal meridians of each eye; Astigmatism <2.50D both eyes; Anisometropia <1.50D SER
  • Investigator has confirmed the following regarding best-corrected distance visual acuity (VA) in habitual spectacles or trial frames using the investigator's preferred VA testing method:; VA is age normal in both eyes1,2; 5-6 years: approximately 20/32 or better, ≤ 0.24 logMAR, ≥ 73 letters; 7-12 years: approximately 20/25 or better, ≤ 0.14 logMAR, ≥ 78 letters; Interocular difference ≤2 logMAR lines (0.2 logMAR) or ≤ 10 letters
  • Wearing spectacles by parent report ≥90% of waking hours ≥30 days duration before enrollment. For children who meet all other inclusion criteria but whose single-vision spectacles are broken or lost within the last 90 days, enrollment can proceed as long as the child was wearing their single-vision spectacles ≥90% of waking hours ≥30 days before the spectacles were broken or lost
  • Gestational age ≥ 32 weeks
  • Birth weight >1500 g
  • Parent(s) and assenting child understand the study procedures and are willing to accept randomization to atropine 0.05%, HAL lenses, atropine combined with HAL lenses, or placebo (i.e., neither active treatment)
  • Parent is willing to participate in a 2- to 4-week run-in phase using nightly artificial tear eyedrops in both eyes
  • Family can return in 2 to 4 weeks for possible randomization
  • Child is willing to refrain from contact lenses for the duration of the study
  • Parent has a phone (or access to a phone) and is willing to be contacted by the clinical site staff
  • Relocation outside of the area of an active PEDIG site within the next 32 months is not anticipated

Who cannot take part

  • Current or previous pharmacologic or light therapy used for myopia treatment
  • Current or prior contact lens wear more than 7 days in the past 12 months
  • Current or previous use of bifocals, progressive-addition lenses, multi-focal contact lenses, or focus- or contrast-modifying spectacle lenses
  • Current or previous use of orthokeratology, rigid gas permeable, or other contact lenses used to slow myopia progression
  • Current or previous myopia control treatment or other uses of atropine, pirenzepine or other anti-muscarinic agents
  • Prior strabismus, intraocular, or refractive surgery
  • Known atropine allergy
  • Known allergy to shellfish
  • Verified history of amblyopia or nystagmus
  • Down syndrome or cerebral palsy
  • Diseases known to affect accommodation, vergence, or ocular motility (e.g., multiple sclerosis, Graves' disease, myasthenia gravis, diabetes mellitus)
  • Any condition that, in the judgment of the investigator, could influence refractive error development
  • Existing conditions in the opinion of the investigator that may affect the long-term health of the eye or require regular pharmacologic treatment that may adversely interact with study medication (e.g., JIA, glaucoma, pre-diabetes)
  • Abnormality of the cornea, lens, central retina, iris, or ciliary body
  • Current constant or intermittent strabismus (phorias are acceptable)
  • Inability to comprehend and/or perform any study-related procedures
  • Individuals who are pregnant, lactating, or intending to become pregnant within the next 30 months; A negative urine pregnancy test at randomization and the 6-, 12-, 18-, and 24-month follow-up visits will be required for individuals who have experienced menarche (at least one menstrual cycle)
  • Immediate family member (spouse, biological or legal guardian, child, sibling, parent) who is investigative site personnel directly affiliated with this study or who is an employee of the Jaeb Center for Health Research
  • Sibling of, or living in the same household as, another child who is concurrently enrolled in the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 5 and 11 years old?

Where in United States

  • UAB Pediatric Eye Care; Birmingham Health CareBirmingham, United StatesContact: Katherine K WeiseTaking people
  • Boston Children's Hospital WalthamBoston, United StatesContact: Aparna Raghuram, O.D., Ph.D.Taking people
  • Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesContact: Noreen Shaikh, ODTaking people
  • Illinois College of OptometryChicago, United StatesContact: Yi Pang, OD, PhDTaking people
  • Ohio State University College of OptometryColumbus, United StatesContact: Ann M Morrison, O.D.Taking people
  • Pediatric Ophthalmology Associates, Inc.Columbus, United StatesContact: Catherine O Jordan, MDTaking people
  • Duke University Eye CenterDurham, United StatesContact: Nathan L Cheung, ODTaking people
  • Marshall B. Ketchum UniversityFullerton, United StatesContact: Angela Chen, O.D., M.S.Taking people
  • Corewell HealthGrand Rapids, United StatesContact: Allegra P Burgher, ODTaking people
  • University of Houston College of OptometryHouston, United StatesContact: Maureen PlaumannTaking people
  • Conestoga EyeLancaster, United StatesContact: Hayley L Woodall, ODTaking people
  • Vanderbilt University Medical Center - Vanderbilt Eye InstituteNashville, United StatesContact: Lori Ann Kehler, ODTaking people
  • Virginia Pediatric Eye CenterNorfolk, United StatesContact: Eric Crouch, MDTaking people
  • Stanford UniversityPalo Alto, United StatesContact: Tawna L Roberts, ODTaking people
  • Pennsylvania College of Optometry, Salus at Drexel UniversityPhiladelphia, United StatesContact: Erin Jenewein, ODTaking people
  • Casey Eye InstitutePortland, United StatesContact: Allison Summers, ODTaking people
  • Rocky Mountain Eye Care AssociatesSalt Lake City, United StatesContact: David Petersen, MDTaking people
  • University of ArizonaTucson, United StatesContact: Jonathan M Holmes, MDTaking people

About the trial

What the trial wants to find out

To date, randomized trials of low-concentration atropine eyedrops and specially designed spectacle lenses to slow the progression of myopia are limited in number and results are inconsistent in non-Asian children.

Read full original descriptionShow less

Although results of some recent randomized clinical trials outside the US are promising, additional studies in children are needed to test the safety and efficacy of low-concentration atropine and specially designed spectacle lenses as treatments to slow the progression of myopia during the peak years for eye growth.

After a run-in phase to demonstrate adherence with nightly eyedrops (artificial tears) and spectacle correction, children 5 to <12 years old with myopia of 0.75D to 6.00D cycloplegic spherical equivalent refractive error (SER) and at least 0.75D myopia in both principal meridians of each eye will be randomized in a 2x2 factorial design to treatment with 1) nightly 0.05% atropine or placebo eyedrops, and 2) spectacles with highly aspherical lenslet target (H.A.L.T.) MAX technology or single vision spectacles, and followed every six months for 24 months. Change in axial length over 24 months and change in SER over 24 months are the primary and secondary outcomes, respectively.

All children will return for a visit at 30 months (after 6 months of no treatment other than single-vision spectacles alone between 24 and 30 months).

The study is funded by the National Eye Institute, part of the NIH, and coordinated by the Jaeb Center for Health Research on behalf of PEDIG. Essilor International, a subsidiary of EssilorLuxottica, the manufacturer of Spectacle lenses with H.A.L.T.* MAX technology, is providing the eyeglasses and financial support for the study. The 0.05% atropine eye drops used in the study are manufactured by Imprimis Rx, a subsidiary of Harrow, Inc.

The 4 groups in the trial

  • Atropine GroupTreatment being tested

    Daily low-concentration atropine (0.05%) eyedrops plus spectacles with single vision lenses (SVL)

    Treatment: Atropine

  • Placebo GroupPlacebo, for comparison

    Daily placebo eyedrops plus spectacles with single-vision lenses (SVL)

    Treatment: Placebo Eyedrops

  • HAL GroupTreatment being tested

    Daily placebo eyedrops plus spectacles with highly aspherical lenslets

    Treatment: Spectacles with HAL and Placebo Eyedrops

  • Combined GroupTreatment being tested

    Daily low-concentration atropine (0.05%) eyedrops plus spectacles with highly aspherical lenslets

    Treatment: Atropine and Spectacles with HAL

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Placebo-controlled Trial of Spectacles With Highly Aspherical Lenslet Target (H.A.L.T.) MAX Technology or 0.05% Atropine to Slow Progression of Myopia in Children
Fit questions
Built from NCT07095894, who can take part
Record updated
2 November 2026